At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SCNX Scienture Holdings, Inc.
Pre-Market Trading 04-09 06:24:24 EDT
0.8544
-0.0760
-8.17%
| High0.9800 | Low0.8300 | Vol188.45K |
| Open0.9400 | D1 Closing0.9304 | Amplitude16.12% |
| Mkt Cap10.69M | Tradable Cap7.04M | Total Shares12.52M |
| T/O172.67K | T/O Rate2.29% | Tradable Shares8.24M |
| P/B-- | ROE-- | EPS0.00 |
| 52wk High-- | 52wk Low-- | P/E-- |
| Dividend-- | Div.Yield-- | ROA-- |
Loading ...
Scienture Sells 3 Subsidiaries to Tollo Health for $5 Million
MT Newswires Live · 04-08 14:14
BRIEF-Scienture Announces The Divestiture Of Its Legacy Subsidiaries
Reuters · 04-08 13:32
Scienture Holdings Inc - Proposed Deal for Total Consideration of $5 Mln
THOMSON REUTERS · 04-08 12:05
Scienture Announces the Divestiture of Its Legacy Subsidiaries for a Total Consideration of $5 Million and Dedicates Its Full Focus to the Branded and Specialty Pharma Segment Through Scienture, Llc.
THOMSON REUTERS · 04-08 12:05
SCIENTURE announces the divestiture of its legacy subsidiaries for a total consideration of $5 million and dedicates its full focus to the Branded and Specialty Pharma segment through Scienture, LLC.
GlobeNewswire · 04-08 12:05
BRIEF-Scienture Holdings Files Prospectus Relates To Resale From Time To Time Of Up To 2.6 Million Shares Of Common Stock By Selling Stockholders
Reuters · 04-04
Scienture files to sell 2.64M shares of common stock for holders
TIPRANKS · 04-04
Scienture CEO says focused on execution, growth, expansion for years ahead
TIPRANKS · 04-03
Scienture Holdings, Inc. Issues Annual Letter to Shareholders
GlobeNewswire · 04-03
Scienture appoints Rath as CCO, enters agreement with Syneos
TIPRANKS · 03-25
SCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a leading Contract Sales Organization
GlobeNewswire · 03-25
Scienture announces draaw on Equity Line of Credit
TIPRANKS · 03-19
Scienture Holdings Inc - to Launch Arbli in U.S. in Q3 2025
THOMSON REUTERS · 03-19
Scienture Holdings Announces Draw on Eloc, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days
THOMSON REUTERS · 03-19
Scienture Says US FDA Approves Oral Liquid Formulation of Hypertension Drug Losartan
MT Newswires Live · 03-18
Scienture Announces the U.S. FDA Approval of Its Nda for Scn-102, to Be Launched as Arblitm, (Losartan Potassium) Oral Suspension, 10Mg/Ml. the Global Market for Losartan Potassium Was Approximately $1.5 Billion in Sales in 2024.
THOMSON REUTERS · 03-18
Scienture Holdings Inc - Arbli Expected to Be Available in U.S. in Q3 2025
THOMSON REUTERS · 03-18
Scienture Holdings Inc - Appoints Eric Sherb as CFO
THOMSON REUTERS · 03-13
BUZZ-U.S. STOCKS ON THE MOVE-CoreCivic, Teladoc, Dynavax
Reuters · 03-06
Scienture Unit, Summit Biosciences Collaborate to Launch Naloxone Spray for Opioid Overdose Treatment in the US
MT Newswires Live · 03-06
Introduction
Company Name.
Scienture Holdings, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
TRxADE HEALTH, Inc. operates as a health services IT company in the United States. The company focuses on digitalizing the retail pharmacy experience by optimizing drug procurement, prescription journey, and patient engagement. It operates the TRxADE drug procurement marketplace, which offers price transparency, purchasing capabilities, and other value-added services; and offers patient centric telehealth services under the Bonum Health brand name. The company was formerly known as Trxade Group, Inc. and changed its name to TRxADE HEALTH, Inc. in June 2021. TRxADE HEALTH, Inc. is based in Lutz, Florida.
Issue price:
--
Invest in Global Markets with Tiger Brokers!Open App